Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection

Angiodynamics

ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Insider Spends US$67k Buying More Shares In AngioDynamics

2024-04-10
Even if it's not a huge purchase, we think it was good to see that James Clemmer, the CEO, President & Director of...

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

2024-04-09
AngioDynamics has made significant restructuring moves, and the potential of newer technologies can support a higher valuation. Learn more on ANGO stock here.

Insiders Buying Zumiez And 3 Other Stocks

2024-04-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript

2024-04-08
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript April 4, 2024 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.14. AngioDynamics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to […]

AngioDynamics Third Quarter 2024 Earnings: Misses Expectations

2024-04-06
AngioDynamics ( NASDAQ:ANGO ) Third Quarter 2024 Results Key Financial Results Revenue: US$75.2m (down 6.9% from 3Q...

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

2024-04-05
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

2024-04-05
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities

2024-04-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results, Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

2024-04-05
LATHAM - AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and...

AngioDynamics Receives 510(k) Clearance for AlphaVac F18 System in Treatment of PE

2024-04-05
LATHAM - AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and...